Drug Profile
APZ 2
Alternative Names: ABCB5+-cells; ABCB5-positive mesenchymal stem cells - RHEACELL; allo-APZ2-ACLF; allo-APZ2-CVU; allo-APZ2-DFU; allo-APZ2-EB; ALLO-APZ2-PAOD; AMESANAR; APZ-1; APZ2; EBESANARLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator RHEACELL
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Varicose ulcer
- Phase III Epidermolysis bullosa
- Phase II Diabetic foot ulcer
- Phase I/II Liver failure
- Preclinical Graft-versus-host disease; Polycystic kidney disease; Transplant rejection
- No development reported Peripheral arterial occlusive disorders
Most Recent Events
- 18 Oct 2023 Phase-III clinical trials in Epidermolysis bullosa (In adolescents, In children, In infants, In adults, In the elderly) in USA (IV) (NCT05838092)
- 01 May 2023 RHEACELL plans a phase III trial for Epidermolysis Bullosa (In Infants, In children, In adolescents, In adults, In elderly) in the US(IV) (NCT05838092)
- 24 Feb 2023 Phase-III clinical trials in Epidermolysis bullosa (In adolescents, In children, In infants, In adults) in Austria (IV) (NCT05464381)